Active Ingredient History
Progesterone is indicated in amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids of uterine cancer. Progesterone, converted from pregnenolone, also serves as an intermediate in the biosynthesis of gonadal steroid hormones and adrenal corticosteroids. Progesterone is a naturally occurring steroid that is secreted by the ovary, placenta, and adrenal gland. In the presence of adequate estrogen, progesterone transforms a proliferative endometrium into a secretory endometrium. Progesterone is necessary to increase endometrial receptivity for implantation of an embryo. Once an embryo is implanted, progesterone acts to maintain a pregnancy. Progesterone shares the pharmacological actions of the progestins. Progesterone binds to the progesterone and estrogen receptors. Target cells include the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. Once bound to the receptor, progesterone will slow the frequency of release of gonadotropin releasing hormone (GnRH) from the hypothalamus and blunt the pre-ovulatory LH (luteinizing hormone) surge. In women who have adequate endogenous estrogen, progesterone transforms a proliferative endometrium into a secretory one. Progesterone is metabolized primarily by the liver largely to pregnanediols and pregnanolones. Pregnanediols and pregnanolones are conjugated in the liver to glucuronide and sulfate metabolites. Progesterone metabolites that are excreted in the bile may be deconjugated and may be further metabolized in the gut via reduction, dehydroxylation, and epimerization. Common progesterone side effects may include: drowsiness, dizziness; breast pain; mood changes; headache; constipation, diarrhea, heartburn; bloating, swelling in your hands or feet; joint pain; hot flashes; or vaginal discharge. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Combination drugs
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Amenorrhea (approved 2007)
Uterine Hemorrhage (approved 2007)
Abnormalities, Drug-Induced (Phase 4)
Abortion, Habitual (Phase 4)
Abortion, Induced (Phase 4)
Abortion, Spontaneous (Phase 4)
Abortion, Threatened (Phase 4)
Alcoholism (Phase 2/Phase 3)
Alzheimer Disease (Phase 3)
Amenorrhea (Phase 4)
Amniotic Fluid (Phase 3)
Angina, Unstable (Phase 3)
Arteriosclerosis (Phase 4)
Atherosclerosis (Phase 2)
Atrophic Vaginitis (Phase 2)
Bipolar Disorder (Phase 2)
Bone Diseases (Phase 3)
Brain Concussion (Phase 4)
Brain Injuries (Phase 3)
Brain Injuries, Traumatic (Phase 3)
Breast Neoplasms (Phase 4)
Bulimia Nervosa (Phase 2)
Cannabis (Phase 2)
Cardiovascular Diseases (Phase 4)
Cervical Intraepithelial Neoplasia (Phase 2)
Cervix Uteri (Phase 3)
Cocaine-Related Disorders (Phase 2/Phase 3)
Contraception (Phase 4)
Coronary Artery Disease (Phase 3)
Coronary Disease (Phase 3)
COVID-19 (Phase 2)
Cryopreservation (Phase 4)
Deficiency Diseases (Phase 2)
Delivery, Obstetric (Phase 4)
Depression (Phase 4)
Depression, Postpartum (Phase 2)
Diabetes Mellitus (Phase 3)
Disability Evaluation (Phase 2)
Dry Eye Syndromes (Phase 2)
Dydrogesterone (Phase 4)
Embryo Implantation (Phase 4)
Embryo Loss (Phase 3)
Embryo Transfer (Phase 4)
Endometrial Hyperplasia (Phase 2/Phase 3)
Endometrial Neoplasms (Phase 3)
Endometriosis (Phase 3)
Endometrium (Phase 4)
Epilepsy (Phase 3)
Estrogens (Phase 2)
Exercise (Phase 3)
Feeding and Eating Disorders (Phase 2)
Female (Phase 1)
Fertility (Phase 4)
Fertilization in Vitro (Phase 4)
Fetal Development (Phase 2)
Flushing (Phase 3)
Genital Diseases, Female (Phase 4)
Genital Diseases, Male (Phase 4)
Glioblastoma (Early Phase 1)
Gliosarcoma (Early Phase 1)
Gonadotropin-Releasing Hormone (Phase 3)
Graft vs Host Disease (Phase 2/Phase 3)
Growth and Development (Phase 2)
Healthy Volunteers (Phase 4)
Heart Defects, Congenital (Phase 2)
Heart Diseases (Phase 3)
HIV Infections (Phase 2)
Hormone Replacement Therapy (Phase 4)
Hormones (Phase 4)
Hyperandrogenism (Phase 1)
Hypercholesterolemia (Phase 3)
Hypertension (Phase 3)
Infant, Premature (Phase 4)
Infertility (Phase 4)
Infertility, Female (Phase 4)
Infertility, Male (Phase 4)
Jervell-Lange Nielsen Syndrome (Phase 2)
Leiomyoma (Phase 2)
Leukomalacia, Periventricular (Phase 2)
Long QT Syndrome (Phase 4)
Luteal Phase (Phase 4)
Male (Phase 4)
Mania (Phase 2)
Memory Disorders (Phase 3)
Menopause (Phase 4)
Menstrual Cycle (Early Phase 1)
Menstruation Disturbances (Phase 3)
Methamphetamine (Early Phase 1)
Morbidity (Phase 3)
Myocardial Ischemia (Phase 3)
Neonatology (Phase 3)
Neoplasms (Phase 2)
Obstetric Labor, Premature (Phase 4)
Orthostatic Intolerance (Phase 2)
Osteoporosis (Phase 4)
Ovarian Hyperstimulation Syndrome (Phase 4)
Perimenopause (Phase 3)
Perinatal Mortality (Phase 3)
Pharmacogenetics (Phase 4)
Pharmacokinetics (Phase 4)
Physiological Effects of Drugs (Phase 4)
Physiology (Phase 1)
Placenta Previa (Phase 2)
Polycystic Ovary Syndrome (Phase 4)
Postmenopause (Phase 4)
Pre-Eclampsia (Phase 2/Phase 3)
Pregnancy (Phase 4)
Pregnancy Complications (Phase 4)
Pregnancy Trimester, Second (Phase 3)
Pregnancy, Twin (Phase 3)
Pregnancy, Unwanted (Phase 1/Phase 2)
Premature Birth (Phase 4)
Premenopause (Phase 4)
Primary Ovarian Insufficiency (Phase 4)
Progesterone (Phase 4)
Progestins (Phase 4)
Prostheses and Implants (Phase 4)
Psychotic Disorders (Phase 2)
Puberty (Phase 1)
Reproduction (Phase 4)
Reproductive Health (Phase 4)
Reproductive Techniques, Assisted (Phase 4)
Sexual Abstinence (Early Phase 1)
Smoking (Phase 4)
Smoking Cessation (Phase 4)
Smoking Reduction (Phase 4)
Stress Disorders, Post-Traumatic (Phase 2/Phase 3)
Stroke (Phase 4)
Substance Withdrawal Syndrome (Phase 4)
Suicidal Ideation (Phase 4)
Sweat (Phase 3)
Systems Biology (Phase 4)
Tendon Injuries (Phase 4)
Thoracic Surgery (Phase 2)
Thrombosis (Phase 3)
Tobacco Use Disorder (Phase 4)
Transgender Persons (Phase 2)
Transsexualism (Phase 4)
Traumatology (Phase 1)
Urinary Calculi (Phase 4)
Uterine Diseases (Phase 3)
Uterus (Phase 3)
Vaginal Diseases (Phase 2)
Vascular Diseases (Phase 2)
Vasomotor System (Phase 3)
Vulvar Lichen Sclerosus (Phase 2)
Weight Gain (Phase 4)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
